A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation

BACKGROUND: Current dose-finding designs for phase I clinical trials can correctly select the MTD in a range of 30–80% depending on various conditions based on a sample of 30 subjects. However, there is still an unmet need for efficiency and cost saving. METHODS: We propose a novel dose-finding desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jin, Zhang, Dapeng, Mu, Rongji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526928/
https://www.ncbi.nlm.nih.gov/pubmed/36183071
http://dx.doi.org/10.1186/s12874-022-01741-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526928/
https://www.ncbi.nlm.nih.gov/pubmed/36183071
http://dx.doi.org/10.1186/s12874-022-01741-3

Ejemplares similares